Onyvax Appoints Richard de Souza As Non Executive Director

London, UK – 15 February 2005: Onyvax Limited, the biotechnology company developing novel cancer therapies, today announces the appointment of Richard de Souza as non-executive director with immediate effect.

Richard de Souza has spent over 25 years working in the pharmaceutical industry. He is the CEO of Archimedes, a new speciality pharma company backed by Warburg Pincus. Prior to Archimedes, he was Director International at Shire Pharmaceuticals, responsible for sales and marketing subsidiaries and operations outside the US as well as the global biologics business. Previously, Richard was President of Europe, Asia, Middle East and Africa with Warner Lambert/Parke Davis and Chairman of European Pharmaceuticals with SmithKline Beecham (SB). Richard has also obtained significant US exposure, having been Senior VP and Director of Marketing USA, also for SB.

Commenting on the appointment, Dr. Anthony Walker, CEO of Onyvax, said: “I am delighted to welcome Richard to the Onyvax Board. He brings invaluable industry knowledge and will be a great asset to Onyvax as we advance our pipeline.”

On his appointment, Richard de Souza said: “Onyvax has achieved impressive clinical results with its cancer vaccine programmes. My role will be to support management in exploiting the Company's enormous potential and I very much look forward to the challenges ahead.”

For further information, please contact:

Onyvax
Dr Anthony Walker / Robert Johnson
+44 (0)208 682 9494

Financial Dynamics
Julia Philips / Lucy Briggs
+44 (0)20 7831 3113